Half-year report · Q2
4578.TEDINET S100WFZ0
Period2025-01-01 → 2025-06-30
Filed2025-07-31
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.18T | 2025-01-01 → 2025-06-30 | Cons. | Revenue IFRS |
| Revenue | ¥2.33T | 2024-01-01 → 2024-12-31 | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥1.11T | 2024-01-01 → 2024-06-30 | Cons. | Revenue IFRS |
| Operating income | ¥242.1bn | 2025-01-01 → 2025-06-30 | Cons. | Operating profit loss IFRS |
| Operating income | ¥126.3bn | 2024-01-01 → 2024-06-30 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥226.3bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥335.9bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥142.2bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss before tax IFRS |
| Net income (owners) | ¥173.5bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥343.1bn | 2024-01-01 → 2024-12-31 | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥107.8bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income | ¥175.9bn | 2025-01-01 → 2025-06-30 | Cons. | Profit loss IFRS |
| Net income | ¥110.6bn | 2024-01-01 → 2024-06-30 | Cons. | Profit loss IFRS |
| Total assets | ¥3.79T | at 2025-06-30 | Cons. | Assets IFRS |
| Total assets | ¥3.74T | at 2024-12-31 | Cons. | Assets IFRS |
| Total assets | ¥3.66T | at 2024-06-30 | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥1.00T | at 2025-06-30 | Cons. | Liabilities IFRS |
| Total liabilities | ¥961.1bn | at 2024-12-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥2.79T | at 2025-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.78T | at 2024-12-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.67T | at 2024-06-30 | Cons. | Equity IFRS |
| Net assets / equity | ¥2.44T | at 2023-12-31v | Cons. | Equity IFRS |
| Equity (owners) | ¥2.72T | at 2025-06-30 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.73T | at 2024-12-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥2.62T | at 2024-06-30 | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥411.1bn | at 2025-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥426.2bn | at 2024-12-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥485.9bn | at 2024-06-30 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥513.3bn | at 2023-12-31v | Cons. | Cash and cash equivalents IFRS |
| Operating cash flow | ¥212.7bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥354.6bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥133.0bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in operating activities IFRS |
| Investing cash flow | −¥130.9bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥265.8bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥159.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in investing activities IFRS |
| Financing cash flow | −¥85.4bn | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥189.4bn | 2024-01-01 → 2024-12-31 | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥26.2bn | 2024-01-01 → 2024-06-30 | Cons. | Net cash provided by used in financing activities IFRS |
| EPS (basic) | ¥326.12 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥633.76 | 2024-01-01 → 2024-12-31 | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥198.61 | 2024-01-01 → 2024-06-30 | Cons. | Basic earnings loss per share IFRS |
| Equity ratio | 71.8% | at 2025-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 73.1% | at 2024-12-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 71.6% | at 2024-06-30 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-01-01 → 2025-06-30 | ¥56.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-01-01 → 2025-06-30 | ¥55.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-01-01 → 2025-06-30 | ¥5.0bn |
| Reconciling Itemsreconciling | revenue | 2025-01-01 → 2025-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-01 → 2025-06-30 | −¥1.7bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-01 → 2025-06-30 | −¥27.8bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥15.8bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥15.8bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥9m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥12.9bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥276.1bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥276.0bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥19m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥36.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2025-01-01 → 2025-06-30 | ¥833.8bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2025-01-01 → 2025-06-30 | ¥833.8bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2025-01-01 → 2025-06-30 | ¥215.4bn |
| —segment total | revenue | 2025-01-01 → 2025-06-30 | ¥1.18T |
| —segment total | revenue external | 2025-01-01 → 2025-06-30 | ¥1.18T |
| —segment total | revenue intersegment | 2025-01-01 → 2025-06-30 | ¥1.7bn |
| —segment total | segment profit | 2025-01-01 → 2025-06-30 | ¥269.9bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-01-01 → 2024-06-30 | ¥56.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-01-01 → 2024-06-30 | ¥54.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥1.8bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-01-01 → 2024-06-30 | ¥4.8bn |
| Reconciling Itemsreconciling | revenue | 2024-01-01 → 2024-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-01 → 2024-06-30 | −¥1.8bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-01 → 2024-06-30 | −¥24.2bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥15.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥15.7bn |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥3m |
| jpcrp040300-q2r_E21183-000Consumer Productsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥12.3bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥271.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥271.8bn |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥15m |
| jpcrp040300-q2r_E21183-000Nutraceuticalsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥37.3bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue | 2024-01-01 → 2024-06-30 | ¥766.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | revenue external | 2024-01-01 → 2024-06-30 | ¥766.7bn |
| jpcrp040300-q2r_E21183-000Pharmaceuticalsreportable segment | segment profit | 2024-01-01 → 2024-06-30 | ¥96.0bn |
| —segment total | revenue | 2024-01-01 → 2024-06-30 | ¥1.11T |
| —segment total | revenue external | 2024-01-01 → 2024-06-30 | ¥1.11T |
| —segment total | revenue intersegment | 2024-01-01 → 2024-06-30 | ¥1.8bn |
| —segment total | segment profit | 2024-01-01 → 2024-06-30 | ¥150.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 782
| Item | Context | Value | Unit |
|---|---|---|---|
| Repayments of lease obligations fin cf IFRS | CurrentYTDDuration | -11843000000 | JPY |
| Dividends paid fin cf IFRS | Prior1YTDDuration | -34066000000 | JPY |
| Dividends paid fin cf IFRS | CurrentYTDDuration | -33489000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | Prior1YTDDuration | -413000000 | JPY |
| Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRS | CurrentYTDDuration | － | JPY |
| Net cash provided by used in financing activities IFRS | Prior1YTDDuration | -26161000000 | JPY |
| Net cash provided by used in financing activities IFRS | CurrentYTDDuration | -85383000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | Prior1YTDDuration | -52323000000 | JPY |
| Net increase decrease in cash and cash equivalents before effect of exchange rate changes IFRS | CurrentYTDDuration | -3600000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 513341000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 426173000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | Prior1YTDDuration | 24875000000 | JPY |
| Effect of exchange rate changes on cash and cash equivalents IFRS | CurrentYTDDuration | -11461000000 | JPY |
| Cash and cash equivalents IFRS | Prior1QuarterInstant | 485892000000 | JPY |
| Cash and cash equivalents IFRS | CurrentQuarterInstant | 411111000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 766728000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 271810000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 15666000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 54725000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1108930000000 | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | Prior1YTDDuration | 1108930000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | － | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 15000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 3000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 1753000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1772000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -1772000000 | JPY |
| Intersegment revenue IFRS | Prior1YTDDuration | － | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 766728000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 271826000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 15670000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 56478000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReportableSegmentsMember | 1110702000000 | JPY |
| Revenue IFRS | Prior1YTDDuration_ReconcilingItemsMember | -1772000000 | JPY |
| Revenue IFRS | Prior1YTDDuration | 1108930000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 96025000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 37339000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 12291000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4817000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReportableSegmentsMember | 150474000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration_ReconcilingItemsMember | -24194000000 | JPY |
| Operating profit loss IFRS | Prior1YTDDuration | 126279000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E21183-000PharmaceuticalsReportableSegmentMember | 833782000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E21183-000NutraceuticalsReportableSegmentMember | 276038000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_jpcrp040300-q2r_E21183-000ConsumerProductsReportableSegmentMember | 15836000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 55110000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReportableSegmentsMember | 1180766000000 | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenue from external customers IFRS | CurrentYTDDuration | 1180766000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |